Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS. Kuhle J, Daizadeh N, Benkert P, Maceski A, et al. Mult Scler 2022;28:573-582.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kuhle J, Daizadeh N, Benkert P, Maceski A, et al. Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS. Mult Scler 2022;28:573-582.
PMID: 34378446